Inaugural chair Dr. Blase Polite recaps the productive first year of ASCO’s Health Policy Committee, which works to ensure that ASCO remains a leading advocate for a cancer care system that protects p
The AI-powered ASCO Guidelines Assistant provides fast, intuitive, and easy interaction with ASCO’s clinical practice guidelines, facilitating high-quality, evidence-based care delivery in a rapidly evolving…
The AI-powered ASCO Guidelines Assistant provides fast, intuitive, and easy interaction with ASCO’s clinical practice guidelines, facilitating high-quality, evidence-based care delivery in a rapidly evolving…
Results from the phase 2 PROSPECT trial show that once-daily tirabrutinib could be a potentially effective treatment for patients with relapsed/refractory primary central nervous system…
Phase 2 study researchers were unable to show that duloxetine is more beneficial than placebo in preventing chemotherapy-induced peripheral neuropathy, but the findings may have…
More than 10% of patients with stage I-III estrogen receptor (ER)–negative or ER-low breast cancer treated with neoadjuvant chemotherapy will have an increase in ER…
The AI-powered ASCO Guidelines Assistant provides fast, intuitive, and easy interaction with ASCO’s clinical practice guidelines, facilitating high-quality, evidence-based care delivery in a rapidly evolving…
Experts discuss the current standard of care for patients with EGFR–wild-type locally advanced non–small cell lung cancer.
More than 10% of patients with stage I-III estrogen receptor (ER)–negative or ER-low breast cancer treated with neoadjuvant chemotherapy will have an increase in ER…
A novel triple oral metronomic chemotherapy regimen extends overall survival in the second-line setting compared with standard-of-care options in advanced head and neck cancers, according…
The AI-powered ASCO Guidelines Assistant provides fast, intuitive, and easy interaction with ASCO’s clinical practice guidelines, facilitating high-quality, evidence-based care delivery in a rapidly evolving…
